保肾康联合盐酸罗格列酮治疗糖尿病肾病20例  

Study of 20 cases of Piperazine Ferulate tablets joint Rosiglitazone Hydrochloride treatment of DN

作　　者：杨勇[1] 宋学权[1] 王霄一[1] 施占琴[1] 丁敏[1] 

机构地区：[1]浙江省湖州市第一人民医院肾内科,浙江湖州313000

出　　处：《中国现代医生》2012年第3期77-78,共2页China Modern Doctor

摘　　要：目的评价保肾康联合盐酸罗格列酮治疗糖尿病肾病(diabetic nephropathy,DN)的疗效。方法 40例DN患者分为观察组和对照组各20例。对照组采用保肾康片治疗;观察组在对照组用药的基础上加用盐酸罗格列酮。结果治疗后两组24 h尿蛋白定量、UAER均明显下降,差异有高度统计学意义(P<0.01);观察组UAER下降程度高于对照组,差异有高度统计学意义(P<0.01)。观察组血液流变学各项指标下降程度高于对照组,差异有高度统计学意义(P<0.01)。两组患者均未见明显不良反应。结论保肾康联合盐酸罗格列酮片治疗DN患者疗效佳,安全性高。Objective To evaluate the effection of Piperazine Ferulate Tablets joint Rosiglitazone treatment of DN. Methods All of 40 cases of DN divided into the observation group and the control group. The control group： Piperazine Ferulate Tablets treatment. The observation group： Medication in the way of the control group, the addition of Rosiglitazone. Results After treatment, 24 h urinary protein, UAER of the two groups decreased, significantly different （P 〈 0.01）; After treatment, UAER decreased of the observation group higher than the control group, significant difference （P 〈 0.01）. After treatment, the decline in hemorheological parameters of the observation group was higher than the control group, significantly different （P 〈 0.01）. Two groups of DN patients no significant adverse reactions. Conclusion Piperazine Ferulate Tablets joint Rosiglitazone treatment of DN curative effect is good, side effect was small.

关 键 词：保肾康 罗格列酮:糖尿病肾病 

分 类 号：R587.2[医药卫生—内分泌]